Infliximab is an appropriate second-line therapy in infants with steroid refractory pyoderma gangrenosum

Research output: Contribution to journal › Letter › Contributed › peer-review

Contributors

  • L. M. Lesmeister - , University of Cologne (Author)
  • J. Peitz - , Asklepios Childens Hospital Sankt Augustin (Author)
  • J. C. von Kleist-Retzow - , University of Cologne (Author)
  • M. A. Lee-Kirsch - , Department of Paediatrics (Author)
  • A. Torrelo - , Hospital Infantil Universitario Nino Jesus de Madrid (Author)
  • I. Tantcheva-Poor - , University of Cologne (Author)
  • I. J. Broekaert - , University of Cologne (Author)

Details

Original languageEnglish
Pages (from-to)e376-e378
JournalJournal of the European Academy of Dermatology and Venereology
Volume36
Issue number5
Publication statusPublished - May 2022
Peer-reviewedYes

External IDs

PubMed 35037304

Keywords

Sustainable Development Goals

ASJC Scopus subject areas